Im James J H, Sandoe Claire H
Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada.
Centre for Headache, Women's College Hospital, 76 Grenville St, Toronto, ON, M5S 1B2, Canada.
Curr Neurol Neurosci Rep. 2025 Aug 9;25(1):57. doi: 10.1007/s11910-025-01446-2.
Psychedelics are often queried as a potential therapeutic option in a multitude of conditions, including pain and mental health disorders, with a growing body of patient reports and scientific publications describing potential benefit. This article reviews recent research on psychedelic compounds for treatment of headache disorders.
Observational data, case reports, and a few recent small, controlled trials suggest symptom benefit at sub-hallucinogenic doses for both migraine and cluster headache. There have not been new completed studies of psychedelics in other headache disorders. Safety signals also tend to be favorable, although there are continuing concerns for systemic and psychiatric effects in varying doses, preparations and clinical contexts. While available studies on psychedelics suggest potential benefit in cluster headache and migraine, access remains complex due to legal considerations, and additional studies are needed to confirm their effectiveness and to ensure safety before they can be recommended for use.
迷幻剂常被视作多种病症（包括疼痛和精神健康障碍）的一种潜在治疗选择，越来越多的患者报告和科学出版物描述了其潜在益处。本文综述了迷幻化合物治疗头痛疾病的最新研究。
观察性数据、病例报告以及最近一些小型对照试验表明，亚致幻剂量的迷幻剂对偏头痛和丛集性头痛均有症状改善作用。目前尚无关于迷幻剂治疗其他头痛疾病的新的完整研究。安全性信号总体也较为良好，不过对于不同剂量、制剂和临床环境下的全身及精神影响仍存在持续担忧。虽然现有关于迷幻剂的研究表明其对丛集性头痛和偏头痛有潜在益处，但由于法律因素，获取迷幻剂仍很复杂，在推荐使用之前，还需要更多研究来证实其有效性并确保安全性。
